CERo Therapeutics (NASDAQ:CERO) Upgraded at D Boral Capital
D Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO – Free Report) from a hold rating to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports. Several other equities analysts have also recently issued reports on the company. Maxim Group started coverage on CERo Therapeutics in a research note on […]
D Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO – Free Report) from a hold rating to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports. Several other equities analysts have also recently issued reports on the company. Maxim Group started coverage on CERo Therapeutics in a research note on […]
